Malta - angličtina - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - antineoplastic agents

Kanada - angličtina - Health Canada

david bull laboratories (pty) ltd. - vincristine sulfate - liquid - 1mg - vincristine sulfate 1mg - antineoplastic agents

Kanada - angličtina - Health Canada

david bull laboratories (pty) ltd. - vincristine sulfate - powder for solution - 5mg - vincristine sulfate 5mg - antineoplastic agents

Malta - angličtina - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - antineoplastic agents

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate -

Spojené štáty - angličtina - NLM (National Library of Medicine)

acrotech biopharma llc - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti leukemia therapies. this indication is approved under accelerated approval based on overall response rate [see clinical studies (14)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). marqibo is contraindicated in patients with demyelinating conditions, including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration risk summary based on findings from nonclinical studies and its mechanism of action, marqibo can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1 ),

Spojené kráľovstvo - angličtina - VMD (Veterinary Medicines Directorate)

andres pintaluba, s.a. - colistin sulphate - premix for medicated feeding stuff - antimicrobial - pigs

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; mannitol; water for injections - vincristine sulphate injection is used in the treatment of cancers of the blood (eg. leukaemia or lymphomas), breast, head and neck or lung. it may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. it may be used in a blood disorder known as idiopathic thrombocytopenic purpura (itp) after other treatments have not been successful. vincristine sulphate injection may be given alone or in combination with other anti-cancer medicines.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: water for injections; mannitol; sodium hydroxide; sulfuric acid - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, and wilm's tumor.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilm's tumor.